Pacific Biosciences of California, Inc.

PACB Healthcare Medical Devices

Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024. In the quarter to June 2026, revenue fell 1.91%, EPS was flat, free cash flow fell 31.0% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.73 0.23 −11.73%
Market cap
$609.2M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
3/9
Altman Z
−6.04
Beneish M
−5.14
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 3 5 4
ROE
(205.90%) (213.45%) (273.55%) (929.31%)
ROA
(44.70%) (53.45%) (15.65%) (16.66%)
ROIC
(108.83%) (93.25%) 0.00% (22.22%)
Return on Tangible Assets
(142.61%) (167.41%) (39.14%) (44.27%)
Average Days of Receivables
72.29 80.86 66.94 71.28
Free Cash Flow per Share
(0.44) (0.40) (0.23) (0.26)
Free Cash Flow
(131.44) (118.92) (71.21) (80.48)
Capital Expenditures
(8.65) (7.71) 40.63 37.57
Other line items
Cash ROIC
(13.41%) (12.78%) (25.58%) (9.49%)
Accounts Receivable Turnover
5.15 5.08 5.25 5.03
Accounts Payable Turnover
8.11 6.11 7.24 5.91
Inventory Turnover
1.94 2.11 1.91 1.76
Average Days of Payables
51.79 66.37 49.65 69.25
Days of Inventory on Hand
168.25 157.49 186.16 220.04
Tax Rate
0.00 0.00 0.01 0.01
Research and Development Expense of Revenue
65.91% 60.81% 54.90% 55.47%
Selling, General and Administrative Expense of Revenue
96.44% 88.43% 82.78% 81.43%
Share Based Compensation of Revenue
31.12% 26.04% 23.07% 21.53%
Interest Coverage
(83.51) (79.65) (19.16) (18.15)
Operating CF/Net income
0.24 0.20 0.87 0.90
Depreciation/Fixed assets
22.27 16.44 0.61 0.58
Capex/Depreciation
(0.02) (0.02) 2.76 2.39
Revenue per Share
0.51 0.53 0.52 0.51
Operating CF per Share
(0.41) (0.37) (0.37) (0.38)
Capex per Share
(0.03) (0.03) 0.13 0.12
Capex to Sales
0.06 0.05 (0.25) (0.24)

Fold the line items

Columns are period end dates